A phase 2 study of SP1049C, doxorubicin in P-glycoprotein-targeting pluronics, in patients with advanced adenocarcinoma of the esophagus and gastroesophageal junction.
Authors
Valle, Juan WArmstrong, Anne C
Newman, C
Alakhov, V
Pietrzynski, G
Brewer, Julie
Campbell, S
Corrie, P
Rowinsky, E K
Ranson, Malcolm R
Affiliation
Department of Medical Oncology, Christie Hospital NHS Trust, Wilmslow Road, Manchester M20 4BX, UK. juan.valle@christie.nhs.ukIssue Date
2011-10
Metadata
Show full item recordAbstract
To evaluate the antitumor activity of SP1049C, a novel P-glycoprotein targeting micellar formulation of doxorubicin, consisting of doxorubicin and two non-ionic block copolymers (pluronics), in patients with advanced adenocarcinoma of the esophagus and gastroesophageal junction (GEJ). Patients andCitation
A phase 2 study of SP1049C, doxorubicin in P-glycoprotein-targeting pluronics, in patients with advanced adenocarcinoma of the esophagus and gastroesophageal junction. 2011, 29 (5):1029-37 Invest New DrugsJournal
Investigational New DrugsDOI
10.1007/s10637-010-9399-1PubMed ID
20179989Type
ArticleLanguage
enISSN
1573-0646ae974a485f413a2113503eed53cd6c53
10.1007/s10637-010-9399-1
Scopus Count
Related articles
- Effect of doxorubicin/pluronic SP1049C on tumorigenicity, aggressiveness, DNA methylation and stem cell markers in murine leukemia.
- Authors: Alakhova DY, Zhao Y, Li S, Kabanov AV
- Issue date: 2013
- Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study).
- Authors: Pinto C, Di Fabio F, Siena S, Cascinu S, Rojas Llimpe FL, Ceccarelli C, Mutri V, Giannetta L, Giaquinta S, Funaioli C, Berardi R, Longobardi C, Piana E, Martoni AA
- Issue date: 2007 Mar
- Phase II study of TP300 in patients with advanced gastric or gastro-oesophageal junction adenocarcinoma.
- Authors: Propper D, Jones K, Anthoney DA, Mansoor W, Ford D, Eatock M, Agarwal R, Inatani M, Saito T, Abe M, Evans TR
- Issue date: 2016 Oct 10
- Phase I dose escalation and pharmacokinetic study of pluronic polymer-bound doxorubicin (SP1049C) in patients with advanced cancer.
- Authors: Danson S, Ferry D, Alakhov V, Margison J, Kerr D, Jowle D, Brampton M, Halbert G, Ranson M
- Issue date: 2004 Jun 1
- Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: a randomized, double-blind, multicenter Phase II trial.
- Authors: Yoon HH, Bendell JC, Braiteh FS, Firdaus I, Philip PA, Cohn AL, Lewis N, Anderson DM, Arrowsmith E, Schwartz JD, Gao L, Hsu Y, Xu Y, Ferry D, Alberts SR, Wainberg ZA
- Issue date: 2016 Dec